Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MERTK | Q12866 | 2/20 | 0.36 |
| ▸ | AURKA | O14965 | 7/20 | 0.35 |
| ▸ | EGFR | P00533 | 7/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.35 |
| ▸ | LCK | P06239 | 2/20 | 0.33 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2180189 | 0.98 | AURKA (0.36) | MERTKAURKAEGFRCHEK1LCK | |
| SCHEMBL2180431 | 0.87 | CHEK1 (0.38) | MERTKAURKAEGFRCHEK1LCK | |
| SCHEMBL2178584 | 0.86 | AURKA (0.36) | MERTKAURKAEGFRCHEK1LCK | |
| SCHEMBL2180927 | 0.86 | AURKA (0.37) | MERTKAURKAEGFRCHEK1LCK | |
| SCHEMBL3259242 | 0.85 | AURKA (0.38) | MERTKAURKAEGFRCHEK1LCK | |
| SCHEMBL12409654 | 0.85 | CHEK1 (0.39) | MERTKAURKAEGFRCHEK1LCK | |
| SCHEMBL2180134 | 0.85 | CHEK1 (0.39) | MERTKAURKAEGFRCHEK1LCK | |
| SCHEMBL12409631 | 0.84 | AURKA (0.37) | MERTKAURKAEGFRCHEK1LCK | |
| SCHEMBL2180183 | 0.84 | AURKA (0.37) | MERTKAURKAEGFRCHEK1LCK | |
| SCHEMBL3258517 | 0.83 | AURKA (0.38) | AURKAEGFRCHEK1LCKTNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166163-A1 | SUBSTITUTED FUROPYRIMIDINES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166163-A1 | SUBSTITUTED FUROPYRIMIDINES AND USE THEREOF | DPYD, TPMT, TYMP | MERTK 530/4885AURKA 2987/4885EGFR 4267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.